Abstract
Knowledge of restless legs syndrome (RLS) has greatly increased in recent years due to the many advances that have been made in diagnosis, management and genetics. Tools have been developed that facilitate the diagnosis and treatment of RLS, in particular the essential diagnostic criteria for RLS have been refined, severity scales (IRLS, RLS-6, JHSS) have been developed, as have instruments that improve diagnostic accuracy and assess for specific aspects of RLS such as augmentation. These newly developed tools have been used in recent population-based studies, which have provided a greater understanding of the epidemiology of RLS, and also within patient-based trials.
As far as the genetics of RLS is concerned, linkage studies in RLS families have revealed eight loci but no causally related sequence variant has yet been identified using this approach. Recent genome-wide association studies have identified variants within intronic or intergenic regions of MEIS1, BTBD9, and MAP2K5/LBXCOR1, and PTPRD, raising new pathological hypotheses for RLS. An overview on therapeutic options and recent trials is given based on evidence-based management strategies for this common disorder.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Hogl B, Kiechl S, Willeit J, et al. (2005) Restless legs syndrome: a communitybased study of prevalence, severity, and risk factors. Neurology 64:1920–1924
Tison F, Crochard A, Leger D, Bouee S, Lainey E, El Hasnaoui A (2005) Epidemiology of restless legs syndrome in French adults: a nationwide survey: the INSTANT Study. Neurology 65:239–246
Bjorvatn B, Leissner L, Ulfberg J, et al. (2005) Prevalence, severity and risk factors of restless legs syndrome in the general adult population in two Scandinavian countries. Sleep Med 6:307–312
Berger K, Luedemann J, Trenkwalder C, John U, Kessler C (2004) Sex and the risk of restless legs syndrome in the general population. Arch Intern Med 164:196–202
Sevim S, Dogu O, Camdeviren H, et al. (2003) Unexpectedly low prevalence and unusual characteristics of RLS in Mersin, Turkey. Neurology 61:1562–1569
Hadjigeorgiou GM, Stefanidis I, Dardiotis E, et al. (2007) Low RLS prevalence and awareness in central Greece: an epidemiological survey. Eur J Neurol 14:1275–1280
Ulfberg J, Bjorvatn B, Leissner L, et al. (2007) Comorbidity in restless legs syndrome among a sample of Swedish adults. Sleep Med 8:768–772
Ulfberg J, Nystrom B, Carter N, Edling C (2001) Restless Legs Syndrome among working-aged women. Eur Neurol 46:17–19
Hogl B, Gschliesser V (2007) RLS assessment and sleep questionnaires in practice – lessons learned from Parkinson’s disease. Sleep Med 8(Suppl 2):S7–S12
Walters AS, LeBrocq C, Dhar A, et al. (2003) Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med 4:121–132
Kohnen R, Oertel WH, Stiasny-Kolster K, Benes H, Trenkwalder C (2003) Severity rating of Restless Legs Syndrome: Review of ten years experience with the RLS-6 scales in clinical trials. American Professional Sleep Societies (APSS). Sleep 15:A342
Allen RP, Earley CJ (2001) Validation of the Johns Hopkins restless legs severity scale. Sleep Med 2:239–242
Benes H (2004) A new appoach to improve the reliability and validity of RLS diagnosis: the restless legs syndrome diagnostic index (RLS-DI). Mov Disord 19:S419
Garcia-Borreguero D, Kohnen R, Hogl B, et al. (2007) Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome. Sleep Med 8:455–463
Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J (2003) Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 4:101–119
Happe S, Vennemann M, Evers S, Berger K (2008) Treatment wish of individuals with known and unknown restless legs syndrome in the community. J Neurol (in press) DOI 10.1007/s00415-008-0922-7
Allen RP, Walters AS, Montplaisir J, et al. (2005) Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 165:1286–1292
Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L (2004) Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 5:237–246
Van De Vijver DA, Walley T, Petri H (2004) Epidemiology of restless legs syndrome as diagnosed in UK primary care. Sleep Med 5:435–440
O’Keeffe ST, Egan D, Myers A, Redmond S (2007) The frequency and impact of restless legs syndrome in primary care. Ir Med J 100:539–542
Ferri R, Lanuzza B, Cosentino FI, et al. (2007) A single question for the rapid screening of restless legs syndrome in the neurological clinical practice. Eur J Neurol 14:1016–1021
Benes H, Walters AS, Allen RP, Hening WA, Kohnen R (2007) Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord 22(Suppl 18):S401–S408
Stiasny-Kolster K, Kohnen R, Moller JC, Trenkwalder C, Oertel WH (2006) Validation of the “L-DOPA test” for diagnosis of restless legs syndrome. Mov Disord 21:1333–1339
Michaud M, Poirier G, Lavigne G, Montplaisir J (2001) Restless Legs Syndrome: scoring criteria for leg movements recorded during the suggested immobilization test. Sleep Med 2:317–321
Hening WA, Allen RP, Thanner S, et al. (2003) The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population. Sleep Med 4:137–141
Hening WA, Allen RP, Washburn M, Lesage SR, Earley CJ (2009) The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions ("mimics"). Sleep Med (in press, doi:10.1016/j.sleep.2008.09.015)
Stefansson H, Rye DB, Hicks A, et al. (2007) A genetic risk factor for periodic limb movements in sleep. N Engl J Med 357:639–647
Poewe W, Hogl B (2004) Akathisia, restless legs and periodic limb movements in sleep in Parkinson’s disease. Neurology 63:S12–S16
Comella CL (2006) Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview. J Neural Transm Suppl:349–355
Bassetti CL, Kretzschmar U, Werth E, Baumann CR (2006) Restless legs and restless legs-like syndrome. Sleep Med 7:534
Winkelmann J, Prager M, Lieb R, et al. (2005) “Anxietas tibiarum” Depression and anxiety disorders in patients with restless legs syndrome. J Neurol 252:67–71
Picchietti DL, England SJ, Walters AS, Willis K, Verrico T (1998) Periodic limb movement disorder and restless legs syndrome in children with attention-deficit hyperactivity disorder. J Child Neurol 13:588–594
Hornyak M, Schluter B, Scholle S, Happe S, Trenkwalder C, Kinkelbur J (2004) Restless legs syndrome in childhood. Nervenarzt 75:742–748
Högl B, Allen R (2008) In: Hallett MaP, W (eds) Therapeutics of Parkinson’s disease and other movement disorders Chichester, UK: John Wiley & Sons, Ltd
Billars L, Hicks A, Bliwise D, et al. (2007) Hypertension risk and PLMS in restless legs syndrome. Sleep 30:A297
Hogl B (2007) Periodic limb movements are associated with disturbed sleep. Pro. J Clin Sleep Med 3:12–14
Mahowald MW (2007) Periodic limb movements are NOT associated with disturbed sleep. Con. J Clin Sleep Med 3:15–17
Gschliesser V, Frauscher B, Brandauer E, et al. (2008) PLM detection by actigraphy compared to polysomnography: a validation and comparison of two actigraphs. Sleep Med doi:10.1016/j.sleep.2008.03.015
Schmidauer C, Sojer M, Seppi K, et al. (2005) Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol 58:630–634
Godau J, Schweitzer KJ, Liepelt I, Gerloff C, Berg D (2007) Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome. Mov Disord 22:187–192
Wetter TC, Eisensehr I, Trenkwalder C (2004) Functional neuroimaging studies in restless legs syndrome. Sleep Med 5:401–406
Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ (2001) MRI measurement of brain iron in patients with restless legs syndrome. Neurology 56:263–265
Earley CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP (2000) Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 54:1698–1700
Earley CJ, Connor JR, Beard JL, Clardy SL, Allen RP (2005) Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. Sleep 28:1069–1075
Mizuno S, Mihara T, Miyaoka T, Inagaki T, Horiguchi J (2005) CSF iron, ferritin and transferrin levels in restless legs syndrome. J Sleep Res 14:43–57
Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P (1997) Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 12:61–65
Ondo W, Jankovic J (1996) Restless legs syndrome: clinicoethiologic correlates. Neurology 47:1435–1441
Winkelmann J, Wetter TC, Collado-Seidel V, et al. (2000) Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 23:597–602
Winkelmann J, Muller-Myhsok B, Wittchen HU, et al. (2002) Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families. Ann Neurol 52:297–302
Allen RP, Earley CJ (2000) Defining the phenotype of the restless legs syndrome (RLS) using age-of-symptomonset. Sleep Med 1:11–19
Desautels A, Turecki G, Montplaisir J, Sequeira A, Verner A, Rouleau GA (2001) Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 69:1266–1270
Bonati MT, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G (2003) Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 126:1485–1492
Pichler I, Marroni F, Volpato CB, et al. (2006) Linkage analysis identifies a novel locus for restless legs syndrome on chromosome 2q in a South Tyrolean population isolate. Am J Hum Genet 79:716–723
Chen S, Ondo WG, Rao S, Chen Q, Wang Q (2004) Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p. Am J Hum Genet 74:876–885
Winkelmann J, Lichtner P, Kemlink D, et al. (2006) New loci for restless legs syndrome map to Chromosome 4q and 17p [abstract]. Mov Disord 21:P304
Kemlink D, Plazzi G, Vetrugno R, et al. (2008) Suggestive evidence for linkage for restless legs syndrome on chromosome 19p13. Neurogenetics 9:75–82
Hicks AA, Rye DB, Kristjansson K, Sigmundsson T, Sigurdsson AP, Eiriksdottir I (2005) Population-based confirmation of the 12q RLS locus in Iceland [abstract]. Mov Disord 20:P117
Winkelmann J, Lichtner P, Putz B, et al. (2006) Evidence for further genetic locus heterogeneity and confirmation of RLS-1 in restless legs syndrome. Mov Disord 21:28–33
Levchenko A, Montplaisir JY, Dube MP, et al. (2004) The 14q restless legs syndrome locus in the French Canadian population. Ann Neurol 55:887–891
Lohmann-Hedrich K, Neumann A, Kleensang A, et al. (2008) Evidence for linkage of restless legs syndrome to chromosome 9p: are there two distinct loci? Neurology 70:686–694
Winkelmann J, Muller-Myhsok B (2008) Genetics of restless legs syndrome: a burning urge to move. Neurology 70:664–665
Desautels A, Turecki G, Montplaisir J, et al. (2002) Evidence for a genetic association between monoamine oxidase A and restless legs syndrome. Neurology 59:215–219
Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4:45–51
Winkelmann J, Lichtner P, Schormair B, et al. (2008) Variants in the neuronal nitric oxide synthase (nNOS, NOS1) gene are associated with restless legs syndrome. Mov Disord 23:350–358
Winkelmann J, Schormair B, Lichtner P, et al. (2007) Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet 39:1000–1006
Schormair B, Kemlink D, Roeske D, et al. (2008) PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet 40:946–948
Dasen JS, Tice BC, Brenner-Morton S, Jessell TM (2005) A Hox regulatory network establishes motor neuron pool identity and target-muscle connectivity. Cell 123:477–491
Maeda R, Mood K, Jones TL, Aruga J, Buchberg AM, Daar IO (2001) Xmeis1, a protooncogene involved in specifying neural crest cell fate in Xenopus embryos. Oncogene 20:1329–1342
Gross MK, Dottori M, Goulding M (2002) Lbx1 specifies somatosensory association interneurons in the dorsal spinal cord. Neuron 34:535–549
Stogios PJ, Downs GS, Jauhal JJ, Nandra SK, Prive GG (2005) Sequence and structural analysis of BTB domain proteins. Genome Biol 6:R82
Uetani N, Chagnon MJ, Kennedy TE, Iwakura Y, Tremblay ML (2006) Mammalian motoneuron axon targeting requires receptor protein tyrosine phosphatases sigma and delta. J Neurosci 26:5872–5880
O’Keeffe ST, Gavin K, Lavan JN (1994) Iron status and restless legs syndrome in the elderly. Age Ageing 23:200–203
Trenkwalder C, Hogl B, Benes H, Kohnen R (2008) Augmentation inrestless legs syndrome is associatedwith low ferritin. Sleep Med 9:572–574
Hening W, Allen R, Chaudhuri KR, et al. (2007) Clinical significance of RLS. Mov Disord 22:S395–S400
Allen RP, Ritchie SY (2008) Clinical efficacy of ropinirole for restless legs syndrome is not affected by age at symptom onset. Sleep Med 9:899–902
Trenkwalder C (2007) Restless legs syndrome: overdiagnosed or underdiagnosed? Nat Clin Pract Neurol 3:474–475
Aukerman MM, Aukerman D, Bayard M, Tudiver F, Thorp L, Bailey B (2006) Exercise and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 19:487–493
Trenkwalder C, Hening WA, Montagna P, et al. (2008) Treatment of Restless Legs Syndrome: An evidence-based review and implications for clinical practice. Mov Disord (in press) DOI: 10.1002/mds.22254
Hornyak M, Grossmann C, Kohnen R, et al. (2008) Cognitive behavioural group therapy to improve patients’ strategies for coping with restless legs syndrome: a proof-of-concept trial. J Neurol Neurosurg Psychiatry 79:823–825
Littner MR, Kushida C, Anderson WM, et al. (2004) Practice parameters for the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27:557–559
Vignatelli L, Billiard M, Clarenbach P, et al. (2006) EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol 13:1049–1065
Chesson AL Jr, Wise M, Davila D, et al. (1999) Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 22:961–968
Brodeur C, Montplaisir J, Godbout R, Marinier R (1988) Treatment of restless legs syndrome and periodic leg movements during sleep with L-dopa: a double-blind, controlled study. Neurology 38:1845–1848
Trenkwalder C, Stiasny K, Pollmacher T, et al. (1995) L-dopa therapy of uremic and idiopathic restless legs syndrome: a double-blind, crossover trial. Sleep 18:681–688
Walker SL, Fine A, Kryger MH (1996) L-DOPA/carbidopa for nocturnal movement disorders in uremia. Sleep 19:214–218
Staedt J, Wassmuth F, Ziemann U, Hajak G, Ruther E, Stoppe G (1997) Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crosover trial of pergolide versus L-Dopa. J Neural Transm 104:461–468
Collado-Seidel V, Kazenwadel J, Wetter TC, et al. (1999) A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 52:285–290
Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R (1999) Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep 22:1073–1081
Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S (2004) Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid. J Neurol 251:579–583
Trenkwalder C, Benes H, Grote L, et al. (2007) Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial. Mov Disord 22:696–703
Micozkadioglu H, Ozdemir FN, Kut A, Sezer S, Saatci U, Haberal M (2004) Gabapentin versus levodopa for the treatment of Restless Legs Syndrome in hemodialysis patients: an open-label study. Ren Fail 26:393–397
Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R (1999) Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial. Sleep 22:1073–1081
Trenkwalder C, Hundemer HP, Lledo A, et al. (2004) Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study. Neurology 62:1391–1397
Antonini A, Poewe W (2007) Fibrotic heart-valve reactions to dopamineagonist treatment in Parkinson’s disease. Lancet Neurol 6:826–829
Hofmann C, Penner U, Dorow R, et al. (2006) Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 29:80–86
Benes H (2006) Transdermal lisuride: short-term efficacy and tolerability study in patients with severe restless legs syndrome. Sleep Med 7:31–35
Adler CH, Hauser RA, Sethi K, et al. (2004) Ropinirole for restless legs syndrome: a placebo-controlled crossover trial Neurology 62:1405–1407
Allen R, Becker PM, Bogan R, et al. (2004) Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 27:907–914
Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. (2004) Ropinirole in the treatment of restless legs syndrome: results from a 12-week, randomised, placebo-controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 75:92–97
Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K (2004) Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 19:1414–1423
Bliwise DL, Freeman A, Ingram CD, Rye DB, Chakravorty S, Watts RL (2005) Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome. Sleep Med 6:141–147
Bogan RK, Fry JM, Schmidt MH, Carson SW, Ritchie SY (2006) Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 81:17–27
Happe S, Sauter C, Klosch G, Saletu B, Zeitlhofer J (2003) Gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 48:82–86
Allen R, Becker PM, Bogan R, et al. (2004) Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 27:907–914
Montplaisir J, Karrasch J, Haan J, Volc D (2006) Ropinirole is effective in the long-term management of restless legs syndrome: a randomized controlled trial. Mov Disord 21:1627–1635
Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B (1999) Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology 52:938–943
Partinen M, Hirvonen K, Jama L, et al. (2006) Efficacy and safety of pramipexole in idiopathic restless legs syndrome: a polysomnographic dose-finding study — the PRELUDE study. Sleep Med 7:407–417
Winkelman JW, Sethi KD, Kushida CA, et al. (2006) Efficacy and safety of pramipexole in restless legs syndrome. Neurology 67:1034–1039
Trenkwalder C, Stiasny-Kolster K, Kupsch A, Oertel WH, Koester J, Reess J (2006) Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 21:1404–1410
Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. (2007) Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 22:213–219
Stiasny K, Moller JC, Oertel WH (2000) Safety of pramipexole in patients with restless legs syndrome. Neurology 55:1589–1590
Stiasny-Kolster K, Kohnen R, Schollmayer E, Moller JC, Oertel WH (2004) Patch application of the dopamine agonist rotigotine to patients with moderate to advanced stages of restless legs syndrome: a double-blind, placebo-controlled pilot study. Mov Disord 19:1432–1438
Oertel WH, Benes H, Garcia-Borreguero D, et al. (2008) Efficacy of rotigotine transdermal system in severe restless legs syndrome: A randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 9:228–239
Trenkwalder C, Benes H, Poewe W, et al. (2008) Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 7:595–604
Willis T (1685) The London Practice of Physics. London: Bassett & Croke
Walters AS, Wagner ML, Hening WA, et al. (1993) Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep 16:327–332
Kaplan PW, Allen RP, Buchholz DW, Walters JK (1993) A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 16:717–723
Walters AS, Winkelmann J, Trenkwalder C, et al. (2001) Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 16:1105–1109
Walker JM, Farney RJ, Rhondeau SM, et al. (2007) Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 3:455–461
Teichtahl H, Wang D (2007) Sleep-disordered breathing with chronic opioid use. Expert Opin Drug Saf 6:641–649
Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G (2002) Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 59:1573–1579
Thorp ML, Morris CD, Bagby SP (2001) A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 38:104–108
Lundvall O, Abom PE, Holm R (1983) Carbamazepine in restless legs. A controlled pilot study. Eur J Clin Pharmacol 25:323–324
Telstad W, Sorensen O, Larsen S, Lillevold PE, Stensrud P, Nyberg-Hansen R (1984) Treatment of the restless legs syndrome with carbamazepine: a double blind study. Br Med J (Clin Res Ed) 288:444–446
Montagna P, Sassoli de Bianchi L, Zucconi M, Cirignotta F, Lugaresi E (1984) Clonazepam and vibration in restless legs syndrome. Acta Neurol Scand 69:428–430
Saletu M, Anderer P, Saletu-Zyhlarz G, et al. (2001) Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. Eur Neuropsychopharmacol 11:153–161
Peled R, Lavie P (1987) Double-blind evaluation of clonazepam on periodic leg movements in sleep. J Neurol Neurosurg Psychiatry 50:1679–1681
Horiguchi J, Inami Y, Sasaki A, Nishimatsu O, Sukegawa T (1992) Periodic leg movements in sleep with restless legs syndrome: effect of clonazepam treatment. Jpn J Psychiatry Neurol 46:727–732
Bezerra ML, Martinez JV (2002) Zolpidem in restless legs syndrome. Eur Neurol 48:180–181
Bonnet MH, Arand DL (1990) The use of triazolam in older patients with periodic leg movements, fragmented sleep, and daytime sleepiness. J Gerontol 45:M139–M144
Davis BJ, Rajput A, Rajput ML, Aul EA, Eichhorn GR (2000) A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome. Eur Neurol 43:70–75
Sloand JA, Shelly MA, Feigin A, Bernstein P, Monk RD (2004) A doubleblind, placebo-controlled trial of intravenous iron dextran therapy in patients with ESRD and restless legs syndrome. Am J Kidney Dis 43:663–670
Earley CJ, Heckler D, Allen RP (2004) The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 5:231–235
Earley CJ, Horska A, Mohamed MA, Barker PB, Beard JL, Allen RP (2009) A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 10:206–211
Wagner ML, Walters AS, Coleman RG, Hening WA, Grasing K, Chokroverty S (1996) Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep 19:52–58
Evidente VG, Adler CH, Caviness JN, Hentz JG, Gwinn-Hardy K (2000) Amantadine is beneficial in restless legs syndrome. Mov Disord 15:324–327
Hornyak M, Voderholzer U, Hohagen F, Berger M, Riemann D (1998) Magnesium therapy for periodic leg movements-related insomnia and restless legs syndrome: an open pilot study. Sleep 21:501–505
Benes H, Kohnen R (2008) Validation of an algorithm for the diagnosis of Restless Legs Syndrome: The Restless Legs Syndrome-Diagnostic Index (RLS-DI). Sleep Med doi:10.1016/j.sleep.2008.06.006
Guilleminault C, Cetel M, Philip P (1993) Dopaminergic treatment of restless legs and rebound phenomenon. Neurology 43:445
Earley CJ, Allen RP (2006) Restless legs syndrome augmentation associated with tramadol. Sleep Med 7:592–593
Vetrugno R, La Morgia C, D’Angelo R, et al. (2007) Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord 22:424–427
Zucconi M, Ferri R, Allen R, et al. (2006) The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med 7:175–183
Paulus W, Trenkwalder C (2006) Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol 5:878–886
Allen RP, Earley CJ (1996) Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 19:205–213
Garcia-Borreguero D, Allen RP, Kohnen R, et al. (2007) Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 8:520–530
Ondo W, Romanyshyn J, Vuong KD, Lai D (2004) Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 61:1393–1397
Ferini-Strambi L (2002) Restless legs syndrome augmentation and pramipexole treatment. Sleep Med 3(Suppl):S23–S25
Winkelman JW, Johnston L (2004) Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med 5:9–14
Kohnen R, Benes H, Högl B, Trenkwalder C (2007) Previous augmentation is not predictive for re-occurrence of augmentation under dopaminergic therapy in severe restless legs syndrome. Sleep Med 8:S95
Frauscher B (2008) The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep Med doi: 10.1016/j.sleep.2008.09.007
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trenkwalder, C., Högl, B. & Winkelmann, J. Recent advances in the diagnosis, genetics and treatment of restless legs syndrome. J Neurol 256, 539–553 (2009). https://doi.org/10.1007/s00415-009-0134-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-009-0134-9